Kuguacin J, a triterpeniod from Momordica charantia leaf, modulates the progression of androgen-independent human prostate cancer cell line, PC3

Food and Chemical Toxicology

Volumn 50, Issue 3-4, 2012, Pages 840-847

  Pitchakarn, Pornsiri ^a,d   Suzuki, Shugo ^a   Ogawa, Kumiko ^a,b   Pompimon, Wilart ^c   Takahashi, Satoru ^a   Asamoto, Makoto ^a   Limtrakul, Pornngarm ^d   Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c LAMPANG RAJABHAT UNIVERSITY   (Thailand)

^d Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Bitter melon; Cell growth; Invasion; Kuguacin J; Prostate cancer

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; CYCLINE; GELATINASE A; GELATINASE B; KUGUACIN J; MATRIX METALLOPROTEINASE 14; SURVIVIN; TRITERPENOID; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOMORDICA CHARANTIA; MOUSE; NONHUMAN; PLANT LEAF; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGENS; ANIMALS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA PRIMERS; HUMANS; IN SITU NICK-END LABELING; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; MOMORDICA; PLANT LEAVES; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CUCUMIS; MOMORDICA CHARANTIA;

EID: 84863401567     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.01.009     Document Type: Article

References (51)

1. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-8589.
2. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
3. Basch E., Gabardi S., Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am. J. Health Syst. Pharm. 2003, 60:356-359.
4. Battelli M.G., Polito L., Bolognesi A., Lafleur L., Fradet Y., Stirpe F. Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. Int. J. Cancer 1996, 65:485-490.
5. Bidoli E., Talamini R., Bosetti C., Negri E., Maruzzi D., Montella M., Franceschi S., La Vecchia C. Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann. Oncol. 2005, 16:152-157.
6. Braun-Falco M., Holtmann C., Lordick F., Ring J. Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma. Hautarzt 2006, 57:701-704.
7. Cockett M.I., Murphy G., Birch M.L., O'Connell J.P., Crabbe T., Millican A.T., Hart I.R., Docherty A.J. Matrix metalloproteinases and metastatic cancer. Biochem. Soc. Symp. 1998, 63:295-313.
8. Croci D.O., Cogno I.S., Vittar N.B., Salvatierra E., Trajtenberg F., Podhajcer O.L., Osinaga E., Rabinovich G.A., Rivarola V.A. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J. Cell. Biochem. 2008, 105:381-390.
9. Cunnick J.E., Sakamoto K., Chapes S.K., Fortner G.W., Takemoto D.J. Induction of tumor cytotoxic immune cells using a protein from the bitter melon (Momordica charantia). Cell. Immunol. 1990, 126:278-289.
10. Fidler I.J., Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-895.
11. Ganguly C., De S., Das S. Prevention of carcinogen-induced mouse skin papilloma by whole fruit aqueous extract of Momordica charantia. Eur. J. Cancer Prev. 2000, 9:283-288.
12. Gilles C., Polette M., Seiki M., Birembaut P., Thompson E.W. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab. Invest. 1997, 76:651-660.
13. Giron L.M., Freire V., Alonzo A., Caceres A. Ethnobotanical survey of the medicinal flora used by the Caribs of Guatemala. J. Ethnopharmacol. 1991, 34:173-187.
14. Gronberg H. Prostate cancer epidemiology. Lancet 2003, 361:859-864.
15. Hamasaki K., Kogure K., Ohwada K. A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt. Toxicon 1996, 34:490-495.
16. Kaur M., Agarwal C., Agarwal R. Anticancer and cancer chemopreventive potential of grape seed extract and other grape-based products. J. Nutr. 2009, 139:1806S-1812S.
17. Kelloff G.J., Crowell J.A., Steele V.E., Lubet R.A., Boone C.W., Malone W.A., Hawk E.T., Lieberman R., Lawrence J.A., Kopelovich L., Ali I., Viner J.L., Sigman C.C. Progress in cancer chemoprevention. Ann. N Y Acad. Sci. 1999, 889:1-13.
18. Khan N., Adhami V.M., Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr. Relat. Cancer 2010, 17:R39-52.
19. Lans C., Brown G. Observations on ethnoveterinary medicines in Trinidad and Tobago. Prev. Vet. Med. 1998, 35:125-142.
20. Law B., Hsiao J.K., Bugge T.H., Weissleder R., Tung C.H. Optical zymography for specific detection of urokinase plasminogen activator activity in biological samples. Anal. Biochem. 2005, 338:151-158.
21. Lee-Huang S., Huang P.L., Chen H.C., Bourinbaiar A., Huang H.I., Kung H.F. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 1995, 161:151-156.
22. Li Y., Cozzi P.J. Targeting uPA/uPAR in prostate cancer. Cancer Treat. Rev. 2007, 33:521-527.
23. Licastro F., Franceschi C., Barbieri L., Stirpe F. Toxicity of Momordica charantia lectin and inhibitor for human normal and leukaemic lymphocytes. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1980, 33:257-265.
24. Limtrakul P., Khantamat O., Pintha K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother. Pharmacol. 2004, 54:525-530.
25. Lin S.S., Lai K.C., Hsu S.C., Yang J.S., Kuo C.L., Lin J.P., Ma Y.S., Wu C.C., Chung J.G. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett. 2009, 285:127-133.
26. Liotta L.A., Rao C.N., Wewer U.M. Biochemical interactions of tumor cells with the basement membrane. Annu. Rev. Biochem. 1986, 55:1037-1057.
27. Moldovan G.L., Pfander B., Jentsch S. PCNA, the maestro of the replication fork. Cell 2007, 129:665-679.
28. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274:21491-21494.
29. Ng T.B., Liu W.K., Sze S.F., Yeung H.W. Action of alpha-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines. Gen. Pharmacol. 1994, 25:75-77.
30. Overall C.M., Sodek J. Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases. J. Biol. Chem. 1990, 265:21141-21151.
31. Papathoma A.S., Zoumpourlis V., Balmain A., Pintzas A. Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis. Mol. Carcinog. 2001, 31:74-82.
32. Pitchakarn P., Ogawa K., Suzuki S., Takahashi S., Asamoto M., Chewonarin T., Limtrakul P., Shirai T. Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Cancer Sci. 2010, 101:2234-2240.
33. Pitchakarn P., Ohnuma S., Pintha K., Pompimon W., Ambudkar S.V., Limtrakul P. Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance. J. Nutr. Biochem. 2011.
34. Pitchakarn P., Suzuki S., Ogawa K., Pompimon W., Takahashi S., Asamoto M., Limtrakul P., Shirai T. Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. Cancer Lett. 2011, 306:142-150.
35. Pulukuri S.M., Gondi C.S., Lakka S.S., Jutla A., Estes N., Gujrati M., Rao J.S. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 2005, 280:36529-36540.
36. Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol. Nutr. Food Res. 2008, 52:507-526.
37. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
38. Shi H., Hiramatsu M., Komatsu M., Kayama T. Antioxidant property of Fructus momordicae extract. Biochem. Mol. Biol. Int. 1996, 40:1111-1121.
39. Stetler-Stevenson W.G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990, 9:289-303.
40. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. J. Biol. Chem. 1995, 270:5331-5338.
41. Sun Y., Huang P.L., Li J.J., Huang Y.Q., Zhang L., Lee-Huang S. Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus. Biochem. Biophys. Res. Commun. 2001, 287:983-994.
42. Syed D.N., Khan N., Afaq F., Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol. Biomarkers Prev. 2007, 16:2193-2203.
43. Szliszka E., Krol W. The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur. J. Cancer Prev. 2011, 20:63-69.
44. Tan M.J., Ye J.M., Turner N., Hohnen-Behrens C., Ke C.Q., Tang C.P., Chen T., Weiss H.C., Gesing E.R., Rowland A., James D.E., Ye Y. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem. Biol. 2008, 15:263-273.
45. Thangapazham R.L., Sharma A., Maheshwari R.K. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J. 2006, 8:E443-449.
46. Wang M., Wang T., Liu S., Yoshida D., Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol. 2003, 20:65-72.
47. Welch D.R., Fabra A., Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl. Acad. Sci. USA 1990, 87:7678-7682.
48. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13:781-792.
49. Yodkeeree S., Garbisa S., Limtrakul P. Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA. Acta Pharmacol. Sin. 2008, 29:853-860.
50. Zeng Z.S., Cohen A.M., Guillem J.G. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999, 20:749-755.
51. Zucker S., Conner C., DiMassmo B.I., Ende H., Drews M., Seiki M., Bahou W.F. Thrombin induces the activation of progelatinase A in vascular endothelial cells. J. Biol. Chem. 1995, 270:23730-23738.